Reading

Researchers are evaluating whether low energy selective laser trabeculoplasty SLT is as effective as standard energy SLT for treating glaucoma and ocular hypertension. The study aims to determine if repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications compared to waiting for the effects of standard SLT to wear off before repeating it. This is a phase 3 randomized clinical trial sponsored by the University of Pittsburgh. Participants initially receive either standard energy SLT, where energy levels are adjusted to produce champagne bubbles every 2nd or 3rd spot during a 360-degree treatment, or low energy SLT, delivering 100 spots at 0.4 mJ per spot with energy adjustments based on bubble formation. After 12 months, eligible participants are randomized to either annual repeat low energy SLT or as-needed repeat standard energy SLT. One treatment arm was discontinued following an interim analysis. Throughout the study, participants are monitored at regular intervals up to 48 months to track outcomes such as 12-month and 48-month treatment survival, mean intraocular pressure IOP at multiple time points, and occurrence of IOP spikes. The study involves assessments of eye pressure and glaucoma progression, with follow-up visits scheduled to observe long-term effects and safety. Total participation may extend up to four years, including repeated evaluations and treatments.